fingolimod hydrochloride has been researched along with tricalcium phosphate in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (tricalcium phosphate) | Trials (tricalcium phosphate) | Recent Studies (post-2010) (tricalcium phosphate) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 14,239 | 521 | 5,961 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, W; Ji, AL; Jiang, CP; Lu, X; Qiang, GH; Wang, ZX; Wu, JH; Wu, JY; Zhang, G | 1 |
1 other study(ies) available for fingolimod hydrochloride and tricalcium phosphate
| Article | Year |
|---|---|
Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
Topics: Animals; Apoptosis; Autophagy; Beclin-1; Calcium Phosphates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Lipids; Liver Neoplasms; Male; Mice, Nude; Nanoparticles; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2018 |